Brawn Biotech Ltd.
BSE: BRAWN · Pharmaceuticals · sector
₹25.40BSE close 2026-10-21
Key numbers
Market cap₹8 cr
Price₹25.40
52w high / low₹26 / ₹18
P/E8.8xSector median 27.9x
P/B1.8xSector median 2.9x
Book value₹14.5
Dividend yield–Sector median 0.48%
ROE22.3%Sector median 11.7%
ROCE-1.1%Sector median 12.3%
OPM-2.6%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover-1.4x
Current ratio1.13x
Sales growth 3y-8.6%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹0 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest -1.4x in the last 12 months.
- Net loss in 1 of the last 6 quarters.
- Other income was 58% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹25.40 on 2026-10-21: -1.2% from the 52-week high, +43.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹25.40 · low ₹15.50
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 2 | 6 | 5 | 4 | 2 | 6 |
| EBITDA | -1 | 0 | 0 | -0 | -0 | 0 |
| OPM % | -24.3% | 3.1% | 0.2% | -0.2% | -25.3% | 0.8% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -0 | 0 | 0 | 0 | 1 | 0 |
| EPS (₹) | 1.65 | 0.89 | 0.25 | 0.17 | 1.95 | 0.52 |
| Revenue YoY | -12.4% | +4.8% | ||||
| Profit YoY | – | -37.5% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 9 | 22 | 16 | 13 | 17 | 17 |
| EBITDA | -2 | -0 | -2 | -2 | -0 | -0 |
| Net profit | -2 | -1 | -2 | -2 | 1 | 1 |
| EPS (₹) | -5.25 | -3.04 | -5.14 | 5.87 | 3.26 | 2.89 |
| Revenue growth | +157.9% | -25.8% | -18.4% | +26.2% | – | |
| Profit growth | – | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -8.6% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | +12.7% (2y) | +26.1% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 3 | 4 |
| Borrowings | 0 | 0 |
| Cash & equivalents | 0 | 0 |
| Total assets | 20 | 21 |
| Fixed assets | 0 | 0 |
| Capital work in progress | – | 0 |
| Investments | 0 | 0 |
| Receivables | 3 | 4 |
| Inventory | 10 | 10 |
| Payables | 8 | 14 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 0 | 0 |
| Cash from investing | -0 | -0 |
| Cash from financing | 0 | 0 |
| Capex | 0 | 0 |
| Free cash flow | -0 | 0 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -53.5% | 21.7% |
| ROCE % | -53.4% | 0.1% |
| Debtor days | 93 | 76 |
| Inventory days | 320 | 253 |
| Payable days | 252 | 362 |
| Cash conversion cycle (days) | 161 | -33 |
| Working capital days | 222 | 42 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| BRAWN | ₹8 cr | 8.8x | 1.8x | 22.3% | -1.1% | -2.6% | -8.6% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2018-09-12 | Dividend | Final Dividend Rs 1.0 |
| 2017-09-14 | Dividend | Final Dividend Rs 1.5 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | BRAWN |
| BSE code | 530207 |
| ISIN | INE899B01015 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-21.